Sandbox g23: Difference between revisions

Jump to navigation Jump to search
Line 68: Line 68:
:::: Note: Consider intraventricular γ-globulin for chronic and/or severe disease.
:::: Note: Consider intraventricular γ-globulin for chronic and/or severe disease.


::* [[Poliovirus]]
::* '''Poliovirus'''
:::* Preferred regimen: supportive
:::* Preferred regimen: supportive
::* [[Powassan virus]]
 
::* '''Powassan virus'''
:::* Preferred regimen: supportive
:::* Preferred regimen: supportive
::* [[Rabies virus]]
::* [[Rabies virus]]
:::'''postxposure prophylaxis'''
:::'''postxposure prophylaxis'''

Revision as of 03:41, 7 June 2015

Encephalitis

  • Pathogen-directed antimicrobial therapy[1]
  • Viruses
  • Adenovirus
  • Preferred regimen: supportive
  • B virus (herpes B virus)
  • Established disease
  • Preferred regimen: Valacyclovir 1,000 mg PO tid OR Ganciclovir 5 mg/kg IV q12h for ≥ 14 days until resolution of neurologic symptoms, then Acyclovir 800 mg PO 5 times daily OR Valacyclovir 1 g PO tid indefinitely
  • Alternative regimen: Acyclovir 15 mg/kg IV q8h for ≥ 14 days until resolution of neurologic symptoms, then Acyclovir 800 mg PO 5 times daily OR Valacyclovir 1 g PO tid indefinitely
  • Prophylaxis after bite or scratch
  • Cytomegalovirus (CMV)
  • Preferred regimen: Ganciclovir 5 mg/kg IV q12h for 14–21 days, followed by 5 mg/kg IV qd for maintenance AND Foscarnet 90 mg/kg IV q12h for 14–21 days, followed by 90-120 mg/kg IV qd for maintenance
  • Eastern equine encephalitis virus
  • Preferred regimen: supportive
  • Epstein-Barr virus (EBV)
Note: Acyclovir is not recommended.
  • Hendra virus
  • Preferred regimen: supportive
  • HSV-1 and HSV-2
  • Preferred regimen: Acyclovir 10 mg/kg IV q8h for 14–21 days
  • Preferred regimen (neonates): Acyclovir 20 mg/kg IV q8h for 21 days
  • Human herpesvirus 6 (HHV-6)
  • Preferred regimen: Ganciclovir 5 mg/kg IV q12h for 14–21 days, followed by 5 mg/kg IV qd for maintenance OR Foscarnet 90 mg/kg IV q12h for 14–21 days, followed by 90-120 mg/kg IV qd for maintenance
  • Human immunodeficiency virus (HIV)
  • Influenza virus
  • Japanese encephalitis virus
  • Preferred regimen: supportive
Note: Interferon alpha is not recommended.
  • JC virus
  • Preferred regimen: Reversal or control of immunosuppression OR HAART in patients with AIDS
  • La Crosse virus
  • Preferred regimen: supportive
  • Measles virus
  • Life-threatening disease
  • SSPE
  • Mumps virus
  • Preferred regimen: supportive
  • Murray Valley encephalitis virus
  • Preferred regimen: supportive
  • Nipah virus
  • Nonpolio enteroviruses
  • Preferred regimen: supportive {{}}
Note: Consider intraventricular γ-globulin for chronic and/or severe disease.
  • Poliovirus
  • Preferred regimen: supportive
  • Powassan virus
  • Preferred regimen: supportive
postxposure prophylaxis
  • Preferred regimen: rabies immunoglobulin AND vaccine
after onset of disease
  • Preferred regimen: supportive
  • Preferred regimen: supportive
  • St. Louis encephalitis virus
  • Preferred regimen: supportive
  • Alternative regimen: IFN-a-2b
  • Tickborne encephalitis virus
  • Preferred regimen: supportive
  • Preferred regimen: supportive
  • Varicella zoster virus (VZV)
  • Preferred regimen: supportive
  • Preferred regimen: supportive
  • Bacteria
  • Ehrlichia chaffeensis (human monocytotrophic ehrlichiosis)
with meningitis
without meningitis
  • Fungi
  • Preferred regimen: Amphotericin B deoxycholate AND flucytosine for 2 weeks, followed by fluconazole for 8 weeks ORv Lipid formulation of amphotericin B AND flucytosine for 2 weeks, followed by fluconazole for 8 weeks OR Amphotericin B AND flucytosine for 6–10 weeks
  • Preferred regimen: Liposomal amphotericin B for 4–6 weeks, followed by itraconazole for at least 1 year and until resolution of CSF abnormalities
  • Protozoa
  • Preferred regimen: Quinine OR quinidine OR artesunate OR artemether
  • Alternative regimen: Atovaquone OR proguanil OR Exchange transfusion (less than 10% parasitemia or cere- bral malaria)
  • Helminths
  • Prion
  • Preferred regimen: supportive
  1. Tunkel, Allan R.; Glaser, Carol A.; Bloch, Karen C.; Sejvar, James J.; Marra, Christina M.; Roos, Karen L.; Hartman, Barry J.; Kaplan, Sheldon L.; Scheld, W. Michael; Whitley, Richard J.; Infectious Diseases Society of America (2008-08-01). "The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 47 (3): 303–327. doi:10.1086/589747. ISSN 1537-6591. PMID 18582201.